1392514-36-1

Basic information

• Product Name: C₂₁H₁₈ClN₅O₄S
• Synonyms: C₂₁H₁₈ClN₅O₄S
• CAS NO: 1392514-36-1
• Molecular Weight: 471.924
• Mol File: 1392514-36-1.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: C₂₁H₁₈ClN₅O₄S(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₁H₁₈ClN₅O₄S(1392514-36-1)
• EPA Substance Registry System: C₂₁H₁₈ClN₅O₄S(1392514-36-1)

Safety Data

• Hazardous Substances Data: 1392514-36-1(Hazardous Substances Data)

Upstream product

• 100367-40-6 2-amino-3-nitro-4-methyl-5-bromopyridine 
• 701214-00-8 methyl 2-(4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxoacetate 
• 102618-23-5 iodomethyl 4-chlorophenyl sulfide 
• 7205-90-5 chloromethyl 4-chlorophenyl sulfide 
• 676491-46-6 4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridine 
• 1150310-08-9 C₈H₇ClN₂O*Cl₂HO₂P 
• 917918-83-3 C₈H₇ClN₂O*ClH 
• 917918-79-7 4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridine hydrochloride 
• 695-34-1 2-Amino-4-methylpyridine 
• 98198-48-2 2-amino-5-bromo-4-methylpyridine 
• 142404-82-8 N-(5-bromo-4-methylpyridin-2-yl)acetamide 
• 5327-32-2 2-acetylamino-4-methylpyridine 
• 917918-82-2 C₁₁H₁₅N₃O₄ 
• 917918-81-1 2-(5-bromo-2-methoxy-3-nitropyridin-4-yl)-N,N-dimethylethenamine 

Downstream Products

• 1392514-37-2 C₃₁H₂₈ClN₇O₄S 
• 864953-39-9 1,3-dihydroxy-2-(hydroxymethyl)propan-2-aminium (3-(2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl)-4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)methyl hydrogen phosphate 
• 1392514-39-4 C₂₅H₂₄ClN₇O₄ 

Relevant articles and documents

Preparation of the HIV Attachment Inhibitor BMS-663068. Part 1. Evolution of Enabling Strategies

The development of two enabling routes that led to the production of >1000 kg of BMS-663068 (3) is described. The route identified for the initial 100 kg delivery to support development activities and initial clinical trials involved the conversion of 2-amino-4-picoline to the parent active pharmaceutical ingredient (API), followed by pro-drug installation and deprotection. To eliminate the problematic isolation of the parent API and synthesis of di-t-butyl(chloromethyl)phosphate, a second-generation pro-drug installation route was developed which involved the conversion of a late-stage common intermediate to an N(1)-thioether derivative followed by chloromethylation, displacement with di-t-butylpotassium phosphate, and deprotection. This second strategy resulted in the multikilogram scale preparation of the API in 14 linear steps and ～7% overall yield.